JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that it has completed the drawdown of its combined $1.75 billion bridge loan facilities with Bank Hapoalim B.M. and Bank Leumi USA. The proceeds of the loans will be used towards funding Teva's previously announced acquisition of Barr Pharmaceuticals, Inc. (NYSE: BRL). Teva intends to fund the remaining cash portion of the consideration by using its cash and marketable securities on hand.
